Rituximab;Rituximab

Zeitschrift fur Rheumatologie

Volumn 69, Issue 7, 2010, Pages 594-600

  Feist, E ^a   Dorner T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arthritis, rheumatoid; Rheumatoid factor; Rituximab; Seropositive

Indexed keywords

IMMUNOGLOBULIN G; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; MEDICAL DOCUMENTATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-1;

EID: 77957764458     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0528-1     Document Type: Review

References (30)

1. Bang H, Egerer K, Gauliard A et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503-2511
2. Bastian H, Zinke S, Egerer K et al (2010) Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study. J Rheumatol 37:1069-1071
3. Calabrese LH, Molloy ES (2008) Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67(Suppl 3):iii64-iii65
4. Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10:816-824
5. Chatzidionysiou K, van Vollenhoven RF, Nasononov E et al (2010) [FRI0196] Efficacy of rituximab retreatment in clinical practice: data from the CERRERA Collaboration. Ann Rheum Dis 69 (Suppl3):380
6. Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806
7. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581 (Pubitemid 38758544)
8. Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis [Epub ahead of pring May 24]
9. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390-1400
10. Finckh A, Ciurea A, Brulhart L et al (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:1417-1423
11. Genovese MC, Schiff M, Luggen M et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547-554
12. Gómez-Reino JJ, Sanmartí R, Romero AB et al (2010) [STAT0155] Switching to rituximab vs tnf-inhibitor cycling in patients with an inadequate response to tnf inhibitors: The MIRAR Study. Ann Rheum Dis
13. Gottenberg J, Ravaud P, Bardin T et al (2008) [THU0181] Prospective follow-up of rituximab treatment in 804 patients with refractory rheumatoid arthritis (466 patients/year): tolerance and safety data form the French Registry AIR (Autoimmunity and Rituximab). Ann Rheum Dis 67(Suppl 2):194
14. Isaacs JD, Olech E, Tak PP et al (2009) Autoantibody-positive rheumatoid arthritis (RA) patients (PTS) have enhanced clinical response to rituximab (RTX) When compared with seronegative patients. Ann Rheum Dis 68 (Suppl):442 [abstract]
15. Keystone E, Fleischmann R, Emery P et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896-3908
16. Gottenberg J, Ravaud P, Bardin T et al (2010) Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab (AIR) registry. Arthritis Rheum [Epub ahead of print May 6]
17. Mariette X, Kivitz A, Isaacs JD et al (2009) Effectiveness of rituximab (RTX) + methotrexate (MTX) in patients (PTS) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes. Arthritis Rheum 60 (Suppl):1687 [abstract]
18. Rubbert-Roth A, Tak PP, Zerbini C et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) [Epub ahead of pring May 12]
19. Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210-221
20. Smolen JS, Keystone EC, Emery P et al (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66:143-150
21. Tak PP, Cohen SB, Emery P et al (2007) Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP). Ann Rheum Dis 66 (Suppl):338 [abstract]
22. Thurlings RM, Vos K, Gerlag DM, Tak PP (2008) Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 58:3657-3664
23. Turesson C, Eberhardt K, Jacobsson LT, Lindqvist E (2007) Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis 66:1543-1544
24. Ursum J, Nielen MM, Schaardenburg D van et al (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:R12
25. Venrooij WJ van, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6:37-41
26. Vital EM, Dass S, Rawstron AC et al (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62:1273-1279
27. Vollenhoven RF van, Emery P, Bingham CO 3rd (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558-567
28. Gabay C, Chatzidionysiou K, Nasonov E et al (2010) [OP0051] Effectiveness of different DMARD co-therapies in rituximab-treated rheumatoid arthritis (RA) patients - results of a one-year follow up study form the CERRERA Collaboration. Ann Rheum Dis 69 (Suppl 3):68
29. Wendler J, Soerensen H, Tony H et al (2009) [OP-0025] Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) of leflunomide (LEF) in the German RTX Treatment of Active Rheumatoid Arthritis (RA) in Daily Practice Trial. Ann Rheum Dis 68 (Suppl 3):76
30. Wendler J, Soerensen H, Tony H et al (2009) [FRI0264] Continued treatment of rheumatoid arthritis (RA) with rituximab (RTX) in daily practice: 4. interim analysis of the German Prospective Multicenter Non-Interventional Study. Ann Rheum Dis 68 (Suppl 3):444